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Metastasis is a multistep process in which primary tumor cells are re-established at distant organ sites and develop into
secondary tumors. It accounts for the majority of deaths among patients with solid tumors, necessitating better elucida-
tion of themechanisms involved and development of new therapies to specifically block this process. One of the initiating
events implicated in the onset of metastasis is the epithelial-to-mesenchymal transition (EMT), a cellular process in which
polarized epithelial cells change shape into motile mesenchymal cells. This issue’s Molecular Medicine Select highlights
recent work in an ongoing effort to better understand themolecular mechanisms that regulate tumormetastasis and EMT.
Metastasis Regulation Goes Global
Metastasis is a multistep process requiring primary tumor cells to invade surrounding tissue, to enter and survive in the circu-
latory system, and to extravasate into distant organ sites, where they can grow into secondary tumors. It is thought that met-
astatic cells undergo drastic changes in their gene expression profiles, but how tumor cells acquire such global gene expres-
sion changes in the first place is unclear. To address this question, Han et al. (2008) investigated the role of a nuclear protein
calledSATB1,which acts as a ‘‘genomeorganizer,’’ providing anuclear architecture ontowhich a large number of genomic loci
are tethered and to which chromatin remodeling enzymes and transcription factors are recruited. Increased expression of
SATB1 in breast cancer cell lines and in human breast cancer cells correlates with aggressive tumor phenotypes and shorter
patient survival times. Depletion of SATB1 in highly aggressive breast cancer cells by RNA interference resulted in the altered
expression of hundreds of genes and restoration of acinar polarity to the tumor cells with a consequent decrease in tumor
growth andmetastasis. Meanwhile, enforced expression of SATB1 in a nonmetastatic breast tumor cell line promoted theme-
tastasis of the less-aggressive tumor cells. Comparing gene expression profiles revealed that SATB1 upregulates metastasis
promoting genes and downregulates metastasis suppressor genes involved in cell adhesion, cell-cell junction formation, cell
cycle regulation, cellular signaling, andapoptosis. Theauthors then show thatSATB1,whenbound to thegenomic loci of target
genes, assembles chromatin modifying proteins resulting in epigenetic modifications and corresponding changes in gene
expression. Thus, in primary breast tumor cells, SATB1-mediated gene expression alterations may enable cells to become
metastatic. This finding suggests that SATB1 expression may have value as a prognostic marker of metastatic potential
even in early-stage breast cancer, and may also represent a new therapeutic target for treating metastatic breast tumors.
H.-J. Han et al. (2008). Nature. 452, 187–193.
miRNAs Get into the EMT Business.
Single-stranded small RNAs 18–24 nt in length are calledmicroRNAs (miRNAs). These
miRNAs are known to be involved in the regulation of many key processes in the cell
through posttranscriptional regulation of gene expression. Gregory et al. (2008)
were interested in the possibility that miRNAs could regulate EMT, which is known
to be an initiating event in tumormetastasis. Using an in vitro model in which epithelial
cells are induced to undergo EMT by the growth factor TGFb, these researchers ob-
served downregulation of all five members of the miRNA-200 family as well as miR-
205. When they ectopically expressed these miRNAs in their epithelial cell cultures,
they found thatmiR-200 family members could block TGFb-induced EMT. In addition,
thesemiRNAs could reverse EMT in a process referred to asmesenchymal-to-epithe-
lial transition (MET). Using a target prediction program, they identified the ZEB1 and
SIP1 genes as potential targets of the miR-200 family and miR-205. The transcription
factors ZEB1 and SIP1 have been implicated in repression of the gene encoding the epithelial adhesionmolecule, E-cadherin,
and in promotion of EMT and tumor metastasis. The investigators found that endogenous miR-200 family members andmiR-
205 cooperatively repressed ZEB1 and SIP1 expression. These data are further corroborated by the finding that expression of
these miRNAs is repressed in invasive breast cancer cell lines exhibiting a mesenchymal phenotype and in regions of breast
tumor tissue that do not express E-cadherin. Together, these findings suggest an important role for the miR-200 family and
miR-205 in the silencing of ZEB1 and SIP1 and hence in preventing EMT and the initiation of tumor metastasis.
P.A. Gregory et al. (2008). Nat. Cell Biol. Published online March 30, 2008. 10.1038/ncb1722.
.And So Does the Natural Antisense Transcript
The transcription factor Snail plays an essential role in promoting EMT and can repress expression of epithelial cell genes such
as those encoding E-cadherin either directly or indirectly, activating the transcriptional regulators ZEB1 and its relative SIP1.
Although Snail can transcriptionally activate ZEB1, SIP1 appears to be regulated at the posttranscriptional level. While inves-
tigating the regulation of SIP1 by Snail, Beltran et al. (2008) discovered an uncommon regulatory mechanism involving a
natural antisense transcript or NAT. This natural antisense transcript is known to originate from a spliced SIP1 messenger
RNA generated by transcription of this gene in the opposite direction. However, the regulation of NAT and its precise function
remain unclear. The new study by Beltran et al. reveals that Snail can upregulate NAT expression and that NAT then binds to
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the 50UTR of SIP1, preventing its processing by the spliceosome machinery. Translation of SIP1 is dependent on the intact
50UTR containing an internal ribosome entry site. The authors show that the overexpression of NAT regulates SIP1 protein,
which results in the repression of E-cadherin, a necessary event for the promotion of EMT. This study, and also that by Greg-
ory et al., illustrate the sophisticatedmechanisms that have evolved for fine-tuning EMT, a tightly controlled process that when
dysregulated leads to catastrophic outcomes for the organism.
M. Beltran et al. (2008). Genes Dev. 22, 756–769.
The Mitochondria and Metastasis
Mitochondrial DNA (mtDNA) is considered to be the major cellular target of chemical
carcinogens, and mtDNA mutations occur with high frequency. To study whether
mtDNA mutations play a role in metastatic potential, Ishikawa et al. (2008) used a
cytoplasmic hybrid (cybrid) technology for ‘‘swapping’’ mtDNAbetween cells. In ame-
tastasis mouse model, the authors found that metastatic potential was conferred to
a poorly metastatic cell line by the mtDNA from a highly metastatic mouse cell line.
In the highly metastatic cell lines, they further identified two mtDNA mutations within
the gene encoding NADH dehydrogenase subunit 6, which are responsible for mito-
chondrial respiratory complex I deficiency. This mitochondrial dysfunction is associ-
ated with overproduction of reactive oxygen species (ROS) and upregulation of me-
tastasis-associated genes including those encoding MCL-1, HIF-1a, and VEGF.
Treatment with ROS scavengers led to downregulation of MCL-1 and suppression
of metastatic activity. When the same experiments were performed in two human
cell lines, similar results were observed. Taken together, these data suggest that
mutated mtDNA may contribute to metastatic potential through ROS overproduction
and upregulation of genes that promotemetastasis. In addition to assigning a new role
for mtDNA in mediating metastatic potential, this study also suggests that ROS scav-
engers may have therapeutic potential as inhibitors of metastasis.
K. Ishikawa et al. (2008). Science. Published online April 3, 2008. 10.1126/science.1156906.
Stopping Metastasis in Its Lymphatic Tracks
Although metastasis of solid tumors accounts for the majority of deaths
amongcancer patients, there are currently noclinical therapies to specifically
block metastasis. Metastasis occurs through the dissemination of tumor
cells via the circulatory system. Recent evidence frommouse cancermodels
as well as from pathological analysis of patient tumor samples suggests that
growth of lymphatic vessels (lymphangiogenesis) in or close to tumors is also
associated with metastasis. Normal lymphangiogenesis is mediated by the
secreted growth factor VEGFC (which is overexpressed in tumor cells).
VEGFC induces the growth of lymphatic vessels by activating the VEGFC
receptor expressed in the endothelial cells lining the vessels. In an effort to
better understand this process, Bagri and colleagues (2008) have developed
an antibody to the VEGFC coreceptor, Neuropilin-2 (Nrp2), better known as
a receptor in axon guidance. They show that this antibody blocks VEGFC
from binding to its receptor and inhibits its downstream effects on lymphatic
endothelial cell migration, in part independently of VEGF receptor activation,
as well as formation of new functional lymphatic vessels. Importantly, when
tumorswere treatedwith this antibody, formation of functional tumor associ-
ated lymphatics was blocked, but established lymphatics in normal adult
mice were unaffected. Treatment with the anti-Nrp2 antibody functionally
reduced distant tumor metastases in a mouse mammary carcinoma model
without affecting growth of the primary tumor, likely by blocking spread of
the primary tumor cells via the lymphatic system. This study reveals new
insights into the mechanisms of tumor lymphangiogenesis and how this
processmay contribute tometastasis. The anti-Nrp2 antibodymay therefore
have potential in preventing the early steps of metastasis via the lymphatic
system.
M. Caunt et al. (2008). Cancer Cell 13, 331–342.
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Cancer cells leave the primary tumor (left) and enter
lymphatic vessels (green) eventually entering the
blood (red); from there, they metastasize to distant
organs in this case the lung (metastases, dark
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